Keywords: |
major clinical study; clinical trial; fluorouracil; dose response; drug efficacy; solid tumor; conference paper; capecitabine; gemcitabine; paclitaxel; colorectal cancer; bolus injection; metastasis; quality of life; pharmacodynamics; phase 2 clinical trial; breast cancer; antimetabolites, antineoplastic; antineoplastic activity; tumor xenograft; structure activity relation; breast neoplasms; docetaxel; cancer inhibition; folinic acid; drug toxicity; drug absorption; maximum tolerated dose; taxane derivative; navelbine; anthracycline; administration, oral; deoxycytidine; thymidine phosphorylase; infusion; prodrugs; uft; humans; human; female; priority journal; gastrointestinal mucosa
|